var data={"title":"Sotalol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sotalol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6979?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">see &quot;Sotalol: Drug information&quot;</a> and <a href=\"topic.htm?path=sotalol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sotalol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709415\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life threatening proarrhythmia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of induced arrhythmia, patients initiated or reinitiated on sotalol or sotalol AF and patients who are converted from IV to oral administration should be placed for a minimum of 3 days (on their maintenance dose) in a facility that can provide cardiac resuscitation and continuous electrocardiographic (ECG) monitoring. Do not initiate if baseline QTc interval is longer than 450 msec (Betapace/Betapace AF [when used for atrial fibrillation/atrial flutter], Sotylize, or sotalol injection). If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, prolong the duration of the infusion (injection) or discontinue the drug.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Calculate creatinine clearance (CrCl) prior to dosing; adjust dose based on CrCl. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Product interchange:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not substitute Sorine for sotalol AF because of significant differences in labeling (ie, patient package insert, dosing administration, safety information).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222498\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Betapace;</li>\n      <li>Betapace AF;</li>\n      <li>Sorine;</li>\n      <li>Sotylize</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222499\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Sotalol;</li>\n      <li>CO Sotalol;</li>\n      <li>Dom-Sotalol;</li>\n      <li>Med-Sotalol;</li>\n      <li>Mylan-Sotalol;</li>\n      <li>Novo-Sotalol;</li>\n      <li>Nu-Sotalol;</li>\n      <li>PHL-Sotalol;</li>\n      <li>PMS-Sotalol;</li>\n      <li>PRO-Sotalol;</li>\n      <li>ratio-Sotalol;</li>\n      <li>Rhoxal-sotalol;</li>\n      <li>Riva-Sotalol;</li>\n      <li>Rylosol;</li>\n      <li>Sandoz-Sotalol;</li>\n      <li>ZYM-Sotalol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055457\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class II</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class III</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Beta-Adrenergic Blocker</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445105\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Arrhythmias:</b> Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Sorine/Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace/Sotylize). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PNA &ge; 3 days: Oral: <b>Note:</b> Baseline QT<sub>c</sub> interval and CrCl must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Manufacturer's dosing recommendations are based on doses per m<sup>2</sup> (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (Saul, 2001a; Saul, 2001b). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m<sup>2</sup>, a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m<sup>2</sup> versus those with BSA &ge;0.33 m<sup>2</sup>). For infants and children &le;2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: The manufacturer recommended pediatric dosage of 30 mg/<b>m</b><sup>2</sup>/dose given every 8 hours must be <b>REDUCED</b> by an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for a neonate (PNA: 14 days) is 0.5, so the initial dosage would be (0.5 x 30 mg/m<sup>2</sup>/dose) = 15 mg/m<sup>2</sup>/dose given every 8 hours. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT<sub>c</sub> intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase; for example, the time to reach steady-state in a neonate may be &ge;1 week. </p>\n    (<a href=\"image.htm?imageKey=DRUG%2F78350\" class=\"graphic graphic_figure\">See Age nomogram</a>)\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Alternate dosing: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1-2 mg/kg/day increments; allow at least 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals (L&auml;er, 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proposed target dose: 4 mg/kg/day divided every 8 hours; <b>Note:</b> It is not necessary to increase to target dosage if desired clinical effect has been achieved at a lower dosage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment for toxicity: </b> QT<sub>c</sub> &ge;500 msec during initiation period (Betapace AF): Reduce dose or discontinue sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; dosing in neonates with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QT<sub>c</sub> interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055448\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">see &quot;Sotalol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Baseline QT<sub>c</sub> interval and CrCl must be determined prior to initiation. Dosage must be adjusted to individual response and tolerance; doses should be initiated or increased in a hospital facility that can provide continuous ECG monitoring, recognition and treatment of life-threatening arrhythmias, and CPR:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Pediatric: <b>Note:</b> In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Sorine/Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace AF/Sotylize).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Arrhythmias:</b> Oral: Manufacturer's dosing recommendations are based on doses per m<sup>2</sup> (that are equivalent to the doses recommended in adults) and on pediatric pharmacokinetic and pharmacodynamic studies (Saul 2001a; Saul 2001b). BSA, rather than body weight, better predicted apparent clearance of sotalol; however, for a given dose per m<sup>2</sup>, a larger drug exposure (larger AUC) and greater pharmacologic effects were observed in smaller subjects (ie, those with BSA &lt;0.33 m<sup>2</sup> versus those with BSA &ge;0.33 m<sup>2</sup>). For infants and children &le;2 years of age, the manufacturer recommends a dosage reduction based on an age factor determined from a graph (see below).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: <b>Note:</b> Use with extreme caution if QT<sub>c</sub> is &gt;500 msec while receiving sotalol; reduce the dose or discontinue drug if QT<sub>c</sub> &gt;550 msec.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;2 years: The manufacturer recommended pediatric dosage of 30 mg/<b>m</b><sup>2</sup>/dose every 8 hours must be <b>REDUCED</b> using an age-related factor that is obtained from the graph (see graph). First, obtain the patient's age in months; use the graph to determine where the patient's age (on the logarithmic scale) intersects the age factor curve; read the age factor from the Y-axis; then multiply the age factor by the pediatric dose listed below (ie, the dose for children &gt;2 years); this will result in the proper reduction in dose for age. For example, the age factor for an infant 1 month of age is 0.68, so the initial dosage would be (0.68 x 30 mg/m<sup>2</sup>/dose) = 20 mg/m<sup>2</sup>/dose given every 8 hours. Similar calculations should be made for dosage titrations; increase dosage gradually, if needed; allow adequate time between dosage increments to achieve new steady-state and to monitor clinical response, heart rate and QT<sub>c</sub> intervals; half-life is prolonged with decreasing age (&lt;2 years), so time to reach new steady-state will increase.</p>\n    (<a href=\"image.htm?imageKey=DRUG%2F78350\" class=\"graphic graphic_figure\">See Age nomogram</a>)\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;2 years and Adolescents: Initial: 30 mg/<b>m</b><sup>2</sup>/dose given every 8 hours; increase dosage gradually if needed; allow at least 36 hours between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals; may increase gradually to a maximum of 60 mg/<b>m</b><sup>2</sup>/dose given every 8 hours; not to exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial: Infants, Children, and Adolescents: 2 mg/kg/day divided every 8 hours; if needed, increase dosage gradually by 1 to 2 mg/kg/day increments; allow 3 days between dosage increments to achieve new steady-state and to monitor clinical response, heart rate, and QT<sub>c</sub> intervals; maximum: 10 mg/kg/day (if no limiting side effects occur) (Beaufort-Krol 1997; Colloridi 1992; L&auml;er 2005; Maragnes 1992; Pfammatter 1995; Pfammatter 1997; Tipple 1991); do not exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Proposed target doses: <b>Note:</b> It is not necessary to increase to target dosage if desired clinical effect has been achieved at a lower dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children 1 month to 6 years: 6 mg/kg/day divided every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &gt;6 years and Adolescents: 4 mg/kg/day divided every 8 hours not to exceed adult doses (usual maximum adult daily dose: 320 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ventricular arrhythmias (Betapace, Sorine, Sotylize):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 80 mg twice daily; dose may be increased gradually (in increments of 80 mg/day [Sotalize]) to 160 to 320 mg daily; allow 3 days between dosing increments in order to attain steady-state plasma concentrations and to allow for monitoring of QT intervals</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual range: Most patients respond to a total daily dose of 160 to 320 mg daily in 2 to 3 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum: Some patients with life-threatening refractory ventricular arrhythmias may require total daily doses as high as 480 to 640 mg; however, these doses should only be prescribed when the potential benefit outweighs the increased risk of adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atrial fibrillation or atrial flutter (Betapace AF, Sotylize):</b> Oral: Initial: 80 mg twice daily. If the frequency of relapse does not reduce and excessive QT<sub>c</sub> prolongation does not occur after 3 days, the dose may be increased to 120 mg twice daily; may further increase to a maximum dose of 160 mg twice daily if response is inadequate and QT<sub>c</sub> prolongation is not excessive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QT<sub>c</sub> &ge;500 msec during initiation period (Betapace AF, Sotylize): Reduce dose, prolong the dosing interval (Sotylize), or discontinue sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QT<sub>c</sub> &ge;520 msec (or JT interval &ge;430 msec if the QRS &gt;100 msec) during maintenance therapy (Betapace AF): Reduce dose and carefully monitor QT<sub>c</sub> until &lt;520 msec. If QTc interval &ge;520 msec on the lowest maintenance dose, discontinue sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QT<sub>c</sub> &ge;550 msec (Betapace, Sorine): Reduce dose or discontinue sotalol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; dosing in children with renal impairment has not been investigated; use lower doses or increased dosing intervals; closely monitor clinical response, heart rate and QT<sub>c</sub> interval; allow adequate time between dosage increments to achieve new steady-state, since half-life will be prolonged with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: <b>Note:</b> Impaired renal function can increase the terminal half-life, resulting in increased drug accumulation. Dose escalations in renal impairment should be done after administration of at least 5 to 6 doses at appropriate intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Betapace, Sorine, generic:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;60 mL/minute: Administer every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 60 mL/minute: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: Administer every 36 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Individualize dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Betapace AF, Sotylize:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;60 mL/minute: Administer every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 60 mL/minute: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;40 mL/minute: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Hemodialysis would be expected to reduce sotalol plasma concentrations because sotalol is not bound to plasma proteins and does not undergo extensive metabolism. According to the manufacturers of Betapace and Sorine, extreme caution should be employed if sotalol is used in patients with renal failure undergoing hemodialysis. According to the manufacturer of Betapace AF and Sotylize, use is contraindicated. Multiple cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with hemodialysis (Huynh-Do 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: Peritoneal dialysis does not remove sotalol; supplemental dose is not necessary (Aronoff 2007). Cases of torsades de pointes have been reported when sotalol was used even at low dosages (eg, 80 mg daily) in patients with end-stage renal disease treated with peritoneal dialysis (Dancey 1997; Tang 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely needed because sotalol is not metabolized by the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222468\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sotylize: 5 mg/mL (250 mL, 480 mL) [contains sodium benzoate; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace: 80 mg, 120 mg, 160 mg [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace AF: 80 mg, 120 mg, 160 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sorine: 80 mg, 120 mg, 160 mg, 240 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg, 120 mg, 160 mg, 240 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222453\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055461\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be administered without regard to meals, but should be administered at the same time each day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222493\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect injection from freezing and light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055460\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Betapace, Sorine, Sotylize: Treatment of life-threatening ventricular arrhythmias (eg, sustained ventricular tachycardia) (FDA approved in ages &ge;3 days and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Betapace AF, Sotylize: Maintenance of normal sinus rhythm in patients who have highly symptomatic atrial fibrillation and atrial flutter, but who are currently in normal sinus rhythm [not usually for use in patients with paroxysmal atrial fibrillation/flutter that is easily reversed (eg, by Valsalva maneuver)] (FDA approved in ages &ge;3 days and adults) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> According to the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS), sotalol is not effective for conversion of atrial fibrillation to sinus rhythm but may be used to prevent atrial fibrillation (AHA/ACC/HRS [January, 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222546\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sotalol may be confused with Stadol, Sudafed</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Betapace may be confused with Betapace AF</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High-alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222544\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">There is minimal clinical experience with IV sotalol; however, since exposure is similar between IV and oral sotalol, adverse reactions are expected to be similar.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, bradycardia (dose related), cardiovascular signs and symptoms, cerebrovascular accident, chest pain, cardiac failure (incidence may be higher in patients with risk factors), ECG abnormality, edema, hypertension, hypotension, palpitations, peripheral vascular disorder, presyncope, proarrhythmia, prolonged Q-T interval on ECG (dose related), syncope, torsades de pointes (dose related), vasodilation, worsened ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, dizziness, fatigue (dose related), headache, impaired consciousness, insomnia, mood changes, paresthesia, sensation of cold, sleep disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, hyperhidrosis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Weight changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, change in appetite, colonic disease, decreased appetite, diarrhea, dyspepsia, flatulence, nausea and vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Genitourinary complaint, sexual disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, limb pain, musculoskeletal chest pain, musculoskeletal pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, dyspnea (dose related), pulmonary disease, tracheobronchitis, upper respiratory complaint</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: AICD discharge, fever, laboratory test abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, eosinophilia, increased liver enzymes, leukopenia, paralysis, phlebitis, pruritus, pulmonary edema, skin photosensitivity, thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222476\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sotalol or any component of the formulation; bronchial asthma or related bronchospastic conditions; sinus bradycardia (&lt;50 bpm during waking hours [Betapace/Betapace AF, Sotylize, sotalol injection]); second- or third-degree AV block (unless a functioning pacemaker is present); congenital or acquired long QT syndromes; cardiogenic shock; uncontrolled heart failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Additional contraindications:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Betapace/Betapace AF: When used for atrial fibrillation/flutter, either baseline QTc interval &gt;450 msec or CrCl &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sotylize, sotalol injection: Baseline QTc interval &gt;450 msec (or JT &gt;330 msec if QRS &gt;100 msec [sotalol injection]); CrCl &lt;40 mL/minute; serum potassium &lt;4 mEq/L; sick sinus syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for beta-adrenergic blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222457\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia/hypotension: May cause bradycardia (including heart block) and hypotension. Dose adjustments of agents that slow AV nodal conduction may be necessary when sotalol is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: <b>[US Boxed Warning]: Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation (ie, torsades de pointes). Do not initiate if baseline QTc interval is &gt;450 msec (Betapace/Betapace AF, Sotylize, or sotalol injection). If QTc interval prolongs to 500 msec or exceeds 500 msec during therapy, reduce the dose, prolong the interval between doses, prolong the duration of the infusion (sotalol injection), or discontinue use (Betapace/Betapace AF, Sotylize, sotalol injection). Adjust the dosing interval based on creatinine clearance (CrCl). QTc prolongation is directly related to the concentration of sotalol; reduced CrCl, female gender, reduced heart rate, and large doses increase the risk of QTc prolongation and subsequent torsades de pointes. Patients initiated or reinitiated on sotalol or sotalol AF and patients who are converted from IV to oral administration should be placed for a minimum of 3 days (on their maintenance dose) in a facility that can provide cardiac resuscitation and continuous electrocardiographic (ECG) monitoring.</b> Some experts will initiate oral therapy on an outpatient basis if the patient is in sinus rhythm provided the QT interval and serum potassium are normal and the patient is not receiving any other QT-interval prolonging medications but require inpatient hospitalization if the patient is in atrial fibrillation (AHA/ACC/HRS [January 2014]). Calculation of CrCl must occur prior to administration of the first dose. Dosage should be adjusted gradually with 3 days between dosing increments to achieve steady-state concentrations, and to allow time to monitor QT intervals. Monitor and adjust dose to prevent QTc prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring. Sotalol is contraindicated in patients with bronchial asthma or related bronchospastic conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction abnormality: Consider preexisting conditions such as sick sinus syndrome before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalances: Correct electrolyte imbalances before initiating (especially hypokalemia and hypomagnesemia) because these conditions increase the risk of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): New onset or worsening heart failure may occur during initiation or titration. Use with caution in patients with compensated heart failure; monitor for a worsening of the condition and discontinue if symptoms of heart failure occur. Use is contraindicated in patients with uncontrolled (or decompensated) heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial infarction: Use with caution within the first 2 weeks post-MI, especially in patients with markedly impaired ventricular function (experience limited).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Adjust dosing interval based on CrCl to decrease risk of proarrhythmia; QT interval prolongation is directly related to sotalol concentration.</b> CrCl must be calculated with dose initiation and dose increases. The use of sotalol is contraindicated in patients with CrCl &lt;40 mL/minute (sotalol injection, Sotylize, and Betapace/Betapace AF [when used for atrial fibrillation/atrial flutter]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: Oral: <b>[US Boxed Warning]: Sotalol is indicated for both the treatment of documented life-threatening ventricular arrhythmias (marketed as Betapace/Betapace AF, Sorine, and Sotylize) and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/flutter who are currently in sinus rhythm (marketed as Betapace/Betapace AF and Sotylize). Sorine should not be substituted for sotalol AF.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency. When QTc prolongation occurs, consider weighing the risk of abrupt withdrawal of sotalol with the risk of QTc prolongation. Use of an alternative beta-blocker may be indicated if worsening angina or acute coronary insufficiency occurs when sotalol is withdrawn abruptly due to QTc prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300075\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222462\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12802&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Sotalol. Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222494\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Sotalol peak serum concentrations may be decreased if taken with food. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222464\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222480\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in the initial animal reproduction studies. Sotalol crosses the placenta and is found in amniotic fluid. Adverse events, such as fetal/neonatal bradycardia, hypoglycemia, and reduced birth weight have been observed following in utero exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth are generally recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Sotalol crosses the placenta in concentrations similar to the maternal serum and it is generally preferred for the treatment of fetal atrial flutter (Namouz-Haddad 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The clearance of sotalol is increased during the third trimester of pregnancy, but other pharmacokinetic parameters do not significantly differ from nonpregnant values (O&rsquo;Hare 1983). Use of sotalol may be considered for some cardiac arrhythmias when use of a beta-blocker is needed during pregnancy (ESC [Regitz-Zagrosek 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055456\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum creatinine, magnesium, potassium; heart rate, blood pressure; ECG (eg, QT<sub>c</sub> interval, PR interval); <b>Note:</b> Continuous ECG for a minimum of 3 days with initiation of therapy or dosage increase is suggested; however, patients with an increased sotalol half-life (eg, pediatric patients, especially those &lt;2 years of age, or patients with renal impairment) may require longer monitoring to allow time to achieve steady-state concentrations and observe ECG effect. If baseline QT<sub>c</sub> &gt;450 msec (or JT interval &gt;330 msec if QRS over 100 msec), sotalol (Betapace AF, Sotylize) is contraindicated. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Betapace AF, Sotylize: In addition, during initiation and dosage titration, monitor the QT interval 2 to 4 hours after each dose. If QT<sub>c</sub> interval is &ge;500 msec, reduce dose, prolong the dosing interval (Sotylize), or discontinue sotalol. If the QT<sub>c</sub> interval is &lt;500 msec after 3 days (after fifth or sixth dose in patient receiving once-daily dosing), patient may be discharged on current regimen. Monitor QT<sub>c</sub> interval periodically thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222456\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Beta-blocker which contains both beta-adrenoreceptor-blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) properties </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Class II effects: Increased sinus cycle length, slowed heart rate, decreased AV nodal conduction, and increased AV nodal refractoriness Sotalol has both beta<sub>1</sub>- and beta<sub>2</sub>-receptor blocking activity. The beta-blocking effect of sotalol is a noncardioselective (half maximal at about 80 mg/day and maximal at doses of 320 to 640 mg/day). Significant beta-blockade occurs at oral doses as low as 25 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Class III effects: Prolongation of the atrial and ventricular monophasic action potentials, and effective refractory prolongation of atrial muscle, ventricular muscle, and atrioventricular accessory pathways in both the antegrade and retrograde directions. Sotalol is a racemic mixture of <i>d-</i> and <i>l-</i>sotalol; both isomers have similar Class III antiarrhythmic effects while the <i>l-</i>isomer is responsible for virtually all of the beta-blocking activity. The Class III effects are seen only at oral doses &ge;160 mg/day. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222475\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Rapid; at 1 to 2 hours post dosing (steady-state), reductions in heart rate and cardiac index seen (Winters 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: When administered IV over 5 minutes for ongoing VT, onset of action is ~5 to 10 minutes (Ho 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (Hanyok 1993); decreased ~20% by meals compared with fasting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.2 to 2.4 L/kg (Hanyok 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: None </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 90% to 100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates &le;1 month: 8.4 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children &gt;1 month to 24 months: 7.4 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt;2 years to &lt;7 years: 9.1 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 7 to 12 years: 9.2 hours (Saul 2001b)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults with renal failure (anuric): Up to 69 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Pharmacokinetics of the IV formulation (administered over 5 hours) are similar to the oral formulations (Somberg 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Infants and Children 3 days to 12 years: Mean range: 2 to 3 hours; Adults: 2.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance (apparent) (Saul 2001b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &le;1 month: 11 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children &gt;1 month to 24 months: 32 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &gt;2 years to &lt;7 years: 63 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 7 to 12 years: 95 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222474\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Commercial oral solution is available (5 mg/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 5 mg/mL sotalol syrup may be made with Betapace, Sorine, or Betapace AF tablets and Simple Syrup containing sodium benzoate 0.1% (Syrup, NF). Place 120 mL Syrup, NF in a 6-ounce amber plastic (polyethylene terephthalate) prescription bottle; add five Betapace, Sorine, or Betapace AF 120 mg tablets and shake the bottle to wet the tablets. Allow tablets to hydrate for at least 2 hours, then shake intermittently over &ge;2 hours until the tablets are completely disintegrated; a dispersion of fine particles (water-insoluble inactive ingredients) in syrup should be obtained. <b>Note:</b> To simplify the disintegration process, tablets can hydrate overnight; tablets may also be crushed, carefully transferred into the bottle and shaken well until a dispersion of fine particles in syrup is obtained. Label &quot;shake well&quot;. Stable for 3 months at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) and ambient humidity.</p>\n    <div class=\"reference\">Betapace/Betapace AF prescribing information, Zug, Switzerland: Covis Pharmaceuticals; May 2016.</div>\r\n\n    <div class=\"reference\">Sorine prescribing information, Upsher-Smith, Minneapolis, MN, 2012.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222479\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sotalol HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/10 mL (10 mL): $1,695.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sotylize Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (250 mL): $509.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Betapace AF Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (60): $788.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (60): $965.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (60): $1,207.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Betapace Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $2,200.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $2,694.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $3,367.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sorine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (1): $2.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (1): $3.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (1): $4.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (1): $5.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sotalol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $256.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $341.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">160 mg (100): $427.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (100): $555.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038831\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alosot (UY);</li>\n      <li>Beta-Cardone (GB);</li>\n      <li>Betacor (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Betades (IT);</li>\n      <li>Cardol (AU, TW);</li>\n      <li>Darob (AT, BG, HR, RO);</li>\n      <li>Gilucor (HR, HU);</li>\n      <li>Hipecor (CL);</li>\n      <li>Jutalex (DE);</li>\n      <li>Rentibloc (KR);</li>\n      <li>Solavert (AU);</li>\n      <li>Solet (LK);</li>\n      <li>Sorytmik (UA);</li>\n      <li>Sotacor (AR, AT, AU, BF, BJ, BR, CI, CN, CO, DK, ET, FI, GB, GH, GM, GN, HK, ID, IE, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, SC, SD, SE, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Sotagamma (LV);</li>\n      <li>Sotagard (IN);</li>\n      <li>Sotahexal (DE, HU, SG, VN, ZA);</li>\n      <li>Sotalex (BD, BE, CH, CZ, DE, FR, GR, HN, HU, IT, LU, PH, PL, PT, RU, SI, VN);</li>\n      <li>Sotalex Mite (EE);</li>\n      <li>Sotalol Knoll (HU);</li>\n      <li>Sotalon (KR);</li>\n      <li>Sotapor (ES);</li>\n      <li>Sotax (TR);</li>\n      <li>Sotoger (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; task force on hypertension in pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beaufort-Krol GC and Bink-Boelkens MT, &ldquo;Effectiveness of Sotalol for Atrial Flutter in Children After Surgery for Congenital Heart Disease,&rdquo; <i>Am J Cardiol</i>, 1997, 79(1):92-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9024748/pubmed\" target=\"_blank\" id=\"9024748\">9024748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betapace (sotalol) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betapace AF (sotalol) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; June 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colloridi V, Perri C, Ventriglia F, et al, &ldquo;Oral Sotalol in Pediatric Atrial Ectopic Tachycardia,&rdquo; <i>Am Heart J</i>, 1992, 123(1):254-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1729843 /pubmed\" target=\"_blank\" id=\"1729843 \">1729843 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dancey D, Wulffhart Z, and McEwan P. Sotalol-induced torsades de pointes in patients with renal failure. <i>Can J Cardiol</i>. 1997;13(1):55-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9039065/pubmed\" target=\"_blank\" id=\"9039065\">9039065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &quot;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):S640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackett LP, Wojnar-Horton RE, Dusci LJ, et al, &quot;Excretion of Sotalol in Breast Milk,&quot; <i>Br J Clin Pharmacol</i>, 1990, 29(2):277-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/2306424/pubmed\" target=\"_blank\" id=\"2306424\">2306424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanyok JJ. Clinical pharmacokinetics of sotalol. <i>Am J Cardiol</i>. 1993;72(4):19A-26A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8346722 /pubmed\" target=\"_blank\" id=\"8346722 \">8346722 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huynh-Do U, Wahl C, Sulzer M, et al. Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients. <i>Nephrol Dial Transplant</i>. 1996;11(6):1153-1154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8671988/pubmed\" target=\"_blank\" id=\"8671988\">8671988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&auml;er S, Elshoff JP, Meibohm B, et al, &quot;Development of a Safe and Effective Pediatric Dosing Regimen for Sotalol Based on Population Pharmacokinetics and Pharmacodynamics in Children With Supraventricular Tachycardia,&quot; <i>J Am Coll Cardiol</i>, 2005, 46(7):1322-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/16198851/pubmed\" target=\"_blank\" id=\"16198851\">16198851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lennest&aring;l R, Otterblad Olausson P, K&auml;ll&eacute;n B. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. <i>Eur J Clin Pharmacol</i>. 2009;65(6):615-625.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/19198819/pubmed\" target=\"_blank\" id=\"19198819\">19198819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maragnes P, Tipple M, and Fournier A, &ldquo;Effectiveness of Oral Sotalol for Treatment of Pediatric Arrhythmias,&rdquo; <i>Am J Cardiol</i>, 1992, 69(8):751-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/1546649/pubmed\" target=\"_blank\" id=\"1546649\">1546649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namouz-Haddad S, Koren G. Fetal pharmacotherapy 2: fetal arrhythmia. <i>J Obstet Gynaecol Can</i>. 2013;35(11):1023-1027.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/24246403 /pubmed\" target=\"_blank\" id=\"24246403 \">24246403 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):S729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Hare MF, Leahey W, Murnaghan GA, McDevitt DG. Pharmacokinetics of sotalol during pregnancy. <i>Eur J Clin Pharmacol</i>. 1983;24(4):521-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/6861867 /pubmed\" target=\"_blank\" id=\"6861867 \">6861867 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Hare MF, Murnaghan GA, Russell CJ, et al, &ldquo;Sotalol as a Hypotensive Agent in Pregnancy,&rdquo; <i>Br J Obstet Gynaecol</i>, 1980, 87(9):814-20. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7426541/pubmed\" target=\"_blank\" id=\"7426541\">7426541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfammatter JP and Paul T, &ldquo;New Antiarrhythmic Drug in Pediatric Use: Sotalol,&rdquo; <i>Pediatr Cardiol</i>, 1997, 18(1):28-34. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8960489 /pubmed\" target=\"_blank\" id=\"8960489 \">8960489 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pfammatter JP, Paul T, Lehmann C, et al, &ldquo;Efficacy and Proarrhythmia of Oral Sotalol in Pediatric Patients,&rdquo; <i>J Am Coll Cardiol</i>, 1995, 26(4):1002-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/7560592 /pubmed\" target=\"_blank\" id=\"7560592 \">7560592 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saul JP, Ross B, Schaffer MS, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Sotalol in a Pediatric Population With Supraventricular and Ventricular Tachyarrhythmia,&rdquo; <i>Clin Pharmacol Ther</i>, 2001a, 69(3):145-57. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/11240979/pubmed\" target=\"_blank\" id=\"11240979\">11240979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saul JP, Schaffer MS, Karpawich PP, et al, &ldquo;Single-Dose Pharmacokinetics of Sotalol in a Pediatric Population With Supraventricular and/or Ventricular Tachyarrhythmia,&rdquo; <i>J Clin Pharmacol</i>, 2001b, 41(1):35-43. Foetal supraventricular tachycardia treated with sotalol. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/11144992/pubmed\" target=\"_blank\" id=\"11144992\">11144992</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sonesson SE, Fouron JC, Wesslen-Eriksson E, Jaeggi E, Winberg P. Foetal supraventricular tachycardia treated with sotalol. <i>Acta Paediatr</i>. 1998;87(5):584-587. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/9641744 /pubmed\" target=\"_blank\" id=\"9641744 \">9641744 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorine (sotalol) [prescribing information]. Minneapolis, MN: Upsher-Smith Laboratories Inc; March 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sotylize (sotalol) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tipple M and Sandor G, &ldquo;Efficacy and Safety of Oral Sotalol in Early Infancy,&rdquo; <i>Pacing Clin Electrophysiol</i>, 1991, 14(11 Pt 2):2062-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/ 1721225 /pubmed\" target=\"_blank\" id=\" 1721225 \"> 1721225 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winters SL, Kukin M, Pe E, Stewart D, Deitchman D, Gomes JA. Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. <i>Am J Cardiol</i>. 1993;72(4):38A-43A.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sotalol-pediatric-drug-information/abstract-text/8346725 /pubmed\" target=\"_blank\" id=\"8346725 \">8346725 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12802 Version 181.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709415\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222498\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222499\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055457\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445105\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055448\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222468\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F222453\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055461\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F222493\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055460\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222546\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222544\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222476\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222457\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300075\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222462\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F222494\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222464\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F222480\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055456\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222456\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F222475\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F222474\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222479\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038831\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12802|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/78350\" class=\"graphic graphic_figure\">- Age nomogram</a></li></ul></li><li><div id=\"DRUG_PED/12802|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sotalol-drug-information\" class=\"drug drug_general\">Sotalol: Drug information</a></li><li><a href=\"topic.htm?path=sotalol-patient-drug-information\" class=\"drug drug_patient\">Sotalol: Patient drug information</a></li></ul></div></div>","javascript":null}